pH Pharma Co., Ltd.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Dec 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Thailanstatin analogs (US 10,301,319) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Jan 4, 2027The maintenance fee for Thailanstatin analogs (US 11,691,982) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due May 3, 2027The maintenance fee for 4-(4-Cyano-2-Thioaryl)DIHYDROPYRIMIDINONES and Use Thereof (US 9,174,997) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 23, 2026
- Aug 26 US 8,815,873 Heterocyclic Amides as Rock Inhibitors · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,174,997 | 4-(4-Cyano-2-Thioaryl)DIHYDROPYRIMIDINONES and Use Thereof In force · High confidence | In force | High confidence | |
| US 9,359,362 | Triazolo and Tetrazolo Pyrimidine Derivatives as Hne Inhibitors for Treating Copd In force · Medium confidence | In force | Medium confidence | |
| US 10,676,443 | Method for Producing (4S)-4-[4-Cyano-2-(METHYLSULFONYL)PHENYL]-3,6-Dimethyl-2-OXO-1-[3-(TRIFLUOROMETHYL)PHENYL]-1,2,3,4-Tetrahydro PYRIMIDINE-5-Carbonitrile In force · Medium confidence | In force | Medium confidence | |
| US 10,301,319 | Thailanstatin analogs In force · USPTO record | In force | USPTO record | |
| US 10,815,246 | Thailanstatin analogs In force · USPTO record | In force | USPTO record | |
| US 11,691,982 | Thailanstatin analogs In force · USPTO record | In force | USPTO record | |
| US 10,806,735 | Use of neutrophil elastase inhibitors in liver disease In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 7: 1 patent in force now held by others · 6 lapsed for an unpaid fee · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 no status recorded
Showing 1 to 5 of 5, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. No title is shown: the bulk publication record carries none for these applications, and this site holds no USPTO file history for them.
| Application | Filed | Status |
|---|---|---|
| 17/027,617 | Sep 21, 2020 | No status recorded |
| 17/636,788 | Aug 21, 2020 | No status recorded |
| 16/886,693 | May 28, 2020 | No status recorded |
| 16/648,991 | Sep 19, 2018 | No status recorded |
| 15/775,716 | Nov 9, 2016 | No status recorded |